Amylyx Pharmaceuticals, Inc. $AMLX Stock: Profund Advisors LLC Raises Stake

Profund Advisors LLC lifted its stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 138.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 49,435 shares of the company’s stock after acquiring an additional 28,725 shares during the quarter. Profund Advisors LLC’s holdings in Amylyx Pharmaceuticals were worth $1,439,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in AMLX. BlackRock Inc. acquired a new stake in Amylyx Pharmaceuticals during the 2nd quarter valued at approximately $158,534,000. GSA Capital Partners LLP bought a new position in Amylyx Pharmaceuticals during the 2nd quarter worth approximately $705,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Amylyx Pharmaceuticals by 10.4% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 173,407 shares of the company’s stock worth $3,114,000 after purchasing an additional 16,318 shares during the last quarter. Elmind Capital LP bought a new position in Amylyx Pharmaceuticals during the 2nd quarter worth approximately $2,011,520. Finally, Nantahala Capital Management LLC acquired a new position in shares of Amylyx Pharmaceuticals in the 2nd quarter worth approximately $8,740,845. 95.84% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Amylyx Pharmaceuticals

In related news, insider Gina Mazzariello sold 9,536 shares of the business’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $32.46, for a total transaction of $309,538.56. Following the transaction, the insider owned 190,838 shares in the company, valued at $6,194,601.48. The trade was a 4.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James M. Frates sold 10,810 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $32.36, for a total transaction of $349,811.60. Following the transaction, the chief financial officer directly owned 233,625 shares in the company, valued at approximately $7,560,105. This represents a 4.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 60,374 shares of company stock worth $1,815,257. 10.90% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms have recently commented on AMLX. Citigroup upped their price objective on shares of Amylyx Pharmaceuticals from $32.00 to $39.00 and gave the company a “buy” rating in a research note on Thursday, October 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Wednesday, August 5th. Guggenheim lifted their target price on shares of Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the stock a “buy” rating in a research note on Thursday, August 27th. Mizuho boosted their target price on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, August 18th. Finally, Robert W. Baird upped their price target on shares of Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an “outperform” rating in a research report on Wednesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $40.71.

Amylyx Pharmaceuticals Stock Down 2.8%

NASDAQ AMLX opened at $28.04 on Tuesday. The business has a 50 day simple moving average of $30.68 and a 200 day simple moving average of $20.13. Amylyx Pharmaceuticals, Inc. has a one year low of $10.83 and a one year high of $41.14.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.03). On average, equities analysts predict that Amylyx Pharmaceuticals, Inc. will post -1.48 EPS for the current year.

Amylyx Pharmaceuticals Company Profile